Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Net revenues	$ 33,087	$ 15,490	$ 10,359
Cost of revenues	20,610	10,036	7,013
Gross profit	12,477	5,454	3,346
Operating costs and expenses:
Research, development and clinical trials	43,748	40,381	34,797
Sales and marketing	38,861	21,177	16,406
General and administrative	33,864	24,052	16,602
Total operating costs and expenses	116,473	85,610	67,805
Operating loss	(103,996)	(80,156)	(64,459)
Financial expenses, net	(3,151)	(144)	(12,558)
Loss before income taxes	(107,147)	(80,300)	(77,017)
Income taxes	4,434	382	353
Net loss	$ (111,581)	$ (80,682)	$ (77,370)
Basic and diluted net loss per ordinary share	$ (3.67)	$ (6.46)	$ (6.73)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	30,401,603	12,490,017	11,498,392